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Statin myalgia is not associated with reduced muscle
strength, mass or protein turnover in older male
volunteers, but is allied with a slowing of time to peak
power output, insulin resistance and differential muscle
mRNA expression
Joanne E. Mallinson, Kanagaraj Marimuthu, Andrew Murton, Anna Selby, Kenneth Smith,
Dumitru Constantin-Teodosiu, Michael J. Rennie and Paul L. Greenhaff
MRC/Arthritis Research UK Centre for Musculoskeletal Ageing Research, University of Nottingham, Nottingham NG7 2UH, UK
Key points
 Statins cause muscle-specific side effects, most commonly muscle aches/weakness (myalgia),
particularly in older people. Furthermore, evidence has linked statin use to increased risk of
type 2 diabetes. However, the mechanisms involved are unknown.
 This is the first study to measure muscle protein turnover rates and insulin sensitivity in
statin myalgic volunteers and age-matched, non-statin users under controlled fasting and fed
conditions using gold standard methods.
 We demonstrate in older people that chronic statin myalgia is not associated with deficits in
muscle strength and lean mass or the dysregulation of muscle protein turnover compared to
non-statin users. Furthermore, there were no between-group differences in blood or muscle
inflammatory markers.
 Statin users did, however, show blunting of muscle power output at the onset of dynamic
exercise, increased abdominal adiposity, whole body and leg insulin resistance, and clear
differential expression of muscle genes linked to mitochondrial dysfunction and apoptosis,
which warrant further investigation.
Abstract Statins are associated with muscle myalgia and myopathy, which probably reduce
habitual physical activity. This is particularly relevant to older people who are less active,
sarcopaenic and at increased risk of statin myalgia. We hypothesised that statin myalgia would
be allied to impaired strength and work capacity in older people, and determined whether
differences aligned with divergences in lean mass, protein turnover, insulin sensitivity and the
molecular regulation of these processes. Knee extensor strength and work output during 30
maximal isokinetic contractions were assessed in healthy male volunteers, nine with no statin
use (control 70.4 ± 0.7 years) and nine with statin myalgia (71.5 ± 0.9 years). Whole body and
leg glucose disposal, muscle myofibrillar protein synthesis (MPS) and leg protein breakdown
(LPB) were measured during fasting (5 mU l−1 insulin) and fed (40 mU l−1 insulin + hyper-
aminoacidaemia) euglyceamic clamps. Muscle biopsies were taken before and after each clamp.
Lean mass, MPS, LPB and strength were not different but work output during the initial three
isokinetic contractions was 19% lower (P< 0.05) in statin myalgic subjects due to a delay in time
to reach peak power output. Statin myalgic subjects had reduced whole body (P = 0.05) and leg
(P < 0.01) glucose disposal, greater abdominal adiposity (P < 0.05) and differential expression
of 33 muscle mRNAs (5% false discovery rate (FDR)), six of which, linked to mitochondrial
dysfunction and apoptosis, increased at 1% FDR. Statin myalgia was associated with impaired
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muscle function, increased abdominal adiposity, whole body and leg insulin resistance, and
evidence of mitochondrial dysfunction and apoptosis.
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Introduction
Statin use has been associated with a 30% reduction in
cardiovascular events by reducing cholesterol synthesis
(Vaughan & Gotto, 2004). Statins are generally well
tolerated, but canhavemuscle-specific side effects through
a poorly defined mechanism, ranging from myalgia
(muscle aches or weaknesses with and without elevated
serum creatine kinase (CK) concentration) to, in the
severest case, rhabdomyolysis (typically >10 times the
upper limit of normal serum CK). Meta-analysis of
randomised controlled trials suggest rhabdomyolysis is
rare, although an increased incidence of myalgia is seen in
patients receiving statins compared to placebo (McClure
et al. 2007).
There is currently intense debate as to whether
statins should be prescribed to people at low risk
of cardiovascular disease (Abramson et al. 2013). To
date little consideration has been given to whether this
could be counter-productive in the context of physical
activity. Specifically, there is overwhelming evidence
that physical inactivity, reflected by low aerobic fitness,
is a leading cause of morbidity and mortality (Blair
et al. 2012). Physical inactivity has direct effects on the
development of non-communicable chronic disease, such
as cardiovascular disease and type 2 diabetes (WHO,
2010). In clinical practice it has been reported that
the incidence of muscle pain in statin users increases
with habitual physical activity, with greater numbers of
patients avoiding even moderate exertion during every
day activities (Bruckert et al. 2005). Furthermore, exercise
alongside statin therapy has been shown to increase
CK levels, muscular cramps and muscular weakness in
both sedentary young men (Thompson et al. 1997) and
professional athletes (Sinzinger&O’Grady, 2003).A recent
meta-epidemiological review suggests that exercise and
many drug interventions are similar in terms of their
mortality benefits and that exercise interventions should
be considered as a viable alternative to, or alongside, drug
therapy (Naci & Loannidis, 2013). However, due to the
exacerbation of musculoskeletal problems by exercise in
statin users this should be viewed with some caution.
The average age of statin users is 60 years (Bruckert
et al. 2005), but it is recommended that people >65 years
of age, who are at increased risk of cardiovascular disease,
will benefit the most from statin therapy (Grundy et al.
2004). For many, however, ageing is accompanied by
physical frailty, inactivity, sarcopenia and weakness. Inter-
estingly, older adults taking statins for 2.6 years showed
decreased leg strength and increased falls risk compared
to age-matched controls (Scott et al. 2009). Furthermore,
animal studies suggest statin myopathy is associated
with decreased muscle force (Fuzi et al. 2012), reduced
aerobic capacity and impaired mitochondrial respiration
in skeletalmuscle (Bouitbir et al. 2011). Conversely, Parker
et al. (2012) demonstrated that 6 months of atorvastatin
treatment (80 mg day−1) in healthy individuals across
three age ranges (20–39, 40–54 and 55 years) had
no greater impact on muscle strength than placebo,
although when comparing these asymptomatic subjects
on atorvastatin with myopathic volunteers, isometric leg
strength was significantly lower in the latter. Given this
lack of literature concordance, we aimed to determine
whether people >65 years of age prescribed statins for
4 years, and experiencing muscle-related aches and
pains, presented with impaired muscle function (both
strength and fatigability) and exacerbated muscle mass
loss, and also combine this with comprehensive metabolic
and molecular phenotyping of these same individuals.
There are a number of theories regarding the
mechanistic basis of statin-mediated muscle dysfunction.
In short, evidence suggests statin-mediated dysregulation
of PI3k/Akt and downstream signalling targets may
play a major role in perturbation of muscle protein
and carbohydrate (CHO) metabolism (Mallinson et al.
2009), and may explain the muscle weakness and
fatigability reported in statin myopathic individuals.
Furthermore, pharmacologically increasing muscle CHO
oxidation by administering the pyruvate dehydrogenase
kinase (PDK) inhibitor dichloroacetate concurrently
with simvastatin abolished statin myopathy in vivo in
rodents. This occurred, at least in part, via inhibition of
FOXO-mediated transcription of genes regulating muscle
CHO utilisation and protein breakdown (Mallinson
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et al. 2012). Additionally, meta-data analyses associated
intensive statin therapy (up to 40mgday−1)with increased
risk of new-onset diabetes compared to moderate dose
therapy (Preiss et al. 2011) and a single nucleotide poly-
morphism of 3-hydroxy-3-methylglutaryl–CoA reductase
(HMG–CoA, the target of statin therapy) has also been
linked to increased risk of type 2 diabetes (Swerdlow
et al. 2014). Indeed, regular statin therapy reduces insulin
sensitivity and glucose disposal (Larsen et al. 2013). It
is possible therefore that dampened PI3k/Akt signalling
may be directly related to the statin-mediated decrease
in insulin sensitivity reported in humans. Alternatively,
given that physical inactivity induces insulin resistance,
exemplified by data demonstrating a 2 week transition
from an ambulatory lifestyle to an inactive state induces
insulin resistance and increases central adiposity inhealthy
volunteers (Olsen et al. 2008), it is not unreasonable to
conclude that impaired insulin sensitivity associated with
statin use could result directly from a statin-mediated
decrease in physical activity levels. Indeed, as outlined
above, Bruckert et al. (2005) reported that patients
experiencing statin-related muscle pain avoided even
moderate exertion during every day activities
In the present study we therefore determined whether
older people chronically prescribed statins and reporting
myalgia symptoms presented with (1) reduced muscle
mass, strength and work output during repeated maximal
contractions and (2) elevated leg protein breakdown in
the fasted state and, when exposed to a ‘fed state’ (hyper-
aminoacideamia, hyperinsulinaemia) clamp, and showed
(3) a blunted increase in muscle protein synthesis and
dampened decrease in muscle protein breakdown and
(4) insulin resistance compared to age-matched control
volunteers. We also hypothesised dysregulation of these
physiological responseswould be accompanied by changes
in associated molecular pathways in muscle.
Methods
Ethical approval
This study was approved by the University of Nottingham
Medical School Ethics Committee in accordance with the
Declaration of Helsinki. Before taking part, all subjects
gave informed consent.
Subjects
Nine healthy men (70.4 ± 0.7 years) with a history
of continuous statin use of 4 ± 0.5 years (statin
myalgic subjects) and nine age- (71.5 ± 0.9 years) and
sex-matched volunteers with no history of statin use
(control) participated in this study. Before taking part,
all subjects underwent routine medical screening and
completed a general health questionnaire. Volunteers
reporting any form of chronic muscle pain since starting
statin therapy were recruited into the study. The pre-
sence of statin myalgia was confirmed by measuring
plasma CK concentration and by physical examination
and completion of a muscle pain questionnaire. The
questionnaire was based on the short form McGill pain
questionnaire (Melzack, 1975) and included questions
relating to the characteristics of muscle pain (location,
frequency, type and intensity, triggering and aggravating
factors, and impact of pain on daily activities).
Twenty-four potential myalgic volunteers were screened
and nine were deemed to be suitable for inclusion into
the study. Inclusion criteria included no evidence of
chronic endocrine, renal or respiratory disease; diastolic
blood pressure no higher than 95 mmHg, normal
blood clotting and smoking-free over the past 3 years.
Statin myalgic subjects were included if plasma CK
increased above normal values or they reported muscle
pain not related to an incident and since commencing
statin therapy (determined from the questionnaire).
Subjects on medication apart from statins that affect
muscle metabolism were excluded from the study. Sub-
ject characteristics are presented in Table 1 and detailed
information on statin myalgic subjects in Table 2.
Body composition, muscle isometric strength and
dynamic muscle function
Volunteers underwent a dual-energy X-ray absorp-
tiometry scan to determine whole body and regional
lean and fat masses (Lunar Prodigy; GE Healthcare, Little
Chalfont, UK). Isometric strength was determined (best
of three attempts) in the knee extensor muscles during
a static maximal voluntary contraction using an iso-
metric knee extension unit (Medical Physics, University
of Nottingham, UK). In addition, peak power output and
work output during 30maximal voluntary isokinetic knee
extensions (at a speed of 90 deg s–1) were determined
using an isokinetic dynamometer (Isocom, Eurokinetics,
Nottingham, UK). Subjects were seated securely in the
dynamometer chair with the knee flexed at 90 deg, the
ankle fixed to the lever arm and the actuator axis aligned
to the lateral femoral epicondyle. Subjects were instructed
to push as hard as possible against the lever arm until full
extension was reached and to relax upon flexion until 30
contractions had been completed.
Experimental protocol
The protocol (Fig.1) was designed to allow the
measurement of muscle protein synthesis (by
incorporation of [1,2-13C]leucine into quadriceps
muscle protein) and leg protein breakdown (as the rate
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Table 1. Physical and clinical characteristics of control and statin user groups
Characteristic Control (n = 9) Statin (n = 9) P
Age (years) 71.5 ± 0.9 70.4 ± 0.7 NSD
Height (cm) 175.1 ± 3.0 174.1± 2.9 NSD
Weight (kg) 76.7 ± 3.7 81.2 ± 4.1 NSD
Statin use (years) 0 4 ± 0.5 —
Statin type:
Simvastatin 0 n = 8
Lipitor 0 n = 1
Muscle soreness score 1 4 ± 1.25 <0.001
Plasma CK (U l–1) 114 ± 12.8 92 ± 11.3 NSD
Plasma LDH (U l–1) 359 ± 23.6 348 ± 14.5 NSD
Muscle total creatine (mmol kg dry muscle−1) 117.2 ± 5.8 108.4 ± 6.2 NSD
Muscle ATP (mmol kg dry muscle−1) 18.7 ± 1.1 18.5 ± 1.1 NSD
Plasma TNFα (pg ml−1) 1.0 ± 0.2 1.2 ± 0.2 NSD
Plasma IL6 (pg ml−1) 2.3 ± 0.5 2.8 ± 0.4 NSD
Values are expressed as mean ± SEM and score data are expressed as median ± interquartile range. Muscle soreness score is based
on a scale of 1–10 with 1 being no soreness and 10 being worse possible soreness. CK, creatine kinase; LDH, lactate dehydrogenase;
TNFα, tumour necrosis factor alpha; IL6, interleukin 6; NSD, no significant difference.
Table 2. Statin myalgia subject characteristics
Subject Age
(years)
Statin/dose
(mg)
Duration
on statin
(years)
Duration
of
myalgia
Muscle
soreness
score∗
Exacerbate
symptoms
Alleviate
symptoms
Concurrent medications
1 68 Simvastatin/40 5 >1 year 4 Walking Rest Ramipril, aspirin
2 73 Simvastatin/20 6 >1 year 2 No response No response Omeprazole
3 73 Simvastatin/20 2 >1 year 4 Walking Rest, pain Ramipril, aspirin
killers
4 68 not provided 10 2 months 3 No response No response Atenolol
5 71 Simvastatin/40 1 >1 year 4 Walking Rest None
6 71 Simvastatin/40 4 >1 year 7 No response No response None
7 68 Simvastatin/40 12 >1 year 5 Standing,
lifting
Rest Perindopril, aspirin,
nicotinic acid
8 70 Atorvastatin/80 3 >1 year 2 Lifting,
walking
Rest Ramipril, aspirin
9 70 Simvastatin/40 5 >1 year 3 Activity Rest, pain Omeprazole,
killers bendroflumethiazide,
ramipril
∗Muscle soreness was assessed on a scale of 0 to 10, with 0 being no soreness and 10 being the worse possible soreness.
of dilution of [2H5]phenylalanine) in the fasted (target
serum insulin concentration of 5 mU l−1) and fed state
(target serum insulin concentration of 40 mU l−1 and
a constant infusion of mixed amino acids (AAs) at
10 g h−1) (Rennie et al. 1982). All subjects were asked to
abstain from alcohol and exercise for 48 h prior to the
experimental visit and to arrive in the morning in a fasted
state. Subjects rested semi-supine before a femoral vein
cannula (ES-04150; Arrow Deutschland, Neu-Isenburg,
Germany) was inserted for leg venous blood sampling.
A venous cannula was retrogradely inserted into a
superficial vein on the dorsal surface of the non-dominant
hand which was kept in a hand-warming unit (air
temperature: 50–55°C) to arterialise the venous drainage
of the hand (Gallen & Macdonald, 1990). Cannulas were
also sited at the antecubital fossa in both forearms for
infusion of mixed AAs as well as octreotide, glucagon,
glucose and insulin to clamp insulin concentrations
at various values. Patency of the lines was maintained
using 0.9% NaCl infusions (Baxter Healthcare, Newbury,
UK).
Primed constant infusions of stable isotope labelledAAs
[2H5]phenylalanine and [1,2-13C2]leucine (Cambridge
Isotope Laboratories, Tewksbury, MA, USA) were
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administered for a total period of 240 min. At the
start of the tracer administration, serum insulin was
maintained at fasting concentrations (5 mU l−1) by
the administration of insulin (0.6 mU m−2 min−1;
human Actrapid, Novo, Denmark), endogenous insulin
production was suppressed by infusion of octreotide
(1.8μg kg−1 h−1; Sandostatin, Novartis, Switzerland) and
post-absorptive glucagon concentration was maintained
by infusion of glucagon (10 ng kg−1 h−1). After 120 min,
serum insulin was raised equivalent to the fed state
(40 mU l−1) by the infusion of 40 mU m−2 min−1
insulin. Blood glucose concentration was measured
at 5 min intervals in arterialised venous (AV) blood
samples, and a variable infusion of 20% glucose (Baxter
Healthcare, Newbury, UK) was initiated to maintain a
plasma glucose concentration of 4.5 mmol l−1 during
the insulin infusion. Concurrent with the period of
elevated serum insulin, a primed, constant infusion
of mixed AA (Glamin, Fresenius-Kabi, Runcorn, UK)
was administered at 70 ml h−1 to deliver 10 g h−1
of AAs. AV and femoral venous blood was collected
at 0, +30, +90, +105, +120, +150, +195, +210,
+225 and +240 min for the analysis of blood glucose
and serum insulin (AV only). Femoral arterial blood
flow, and femoral venous and AV blood samples were
taken at 0, +75, +90, +105, +120, +195, +210, +225
and +240 min for blood tracer measurements. Vastus
lateralis muscle biopsies were obtained from the leg in
which the femoral vein cannula was placed using the
percutaneous needle biopsy technique (Bergstrom, 1975)
at 0, 120 and 240 min, and were snap frozen and stored in
liquid nitrogen. Following insulin infusion for 240 min,
glucose infusion was continued for1 h to stabilise blood
glucose concentration, and after which the subjects were
provided with a meal.
Blood glucose and serum insulin
Glucose concentration was measured on AV and femoral
venous blood samples using a glucose analyser (YSI 2300
STATplus; Yellow Springs Instruments, Yellow Springs,
OH, USA) and serum insulin was measured on AV
bloodwith anELISAkit (DX-EIA-2935,DRGInstruments
GmbH, Marburg, Germany).
Muscle metabolites
One portion of each biopsy sample was freeze dried
and dissected free of visible blood and connective
tissue, powdered and used for the determination of
muscle ATP, phosphocreatine (PCr) and free creatine,
using a modification of the spectrophotometric method
of Harris (1974).
Muscle pyruvate dehydrogenase complex (PDC)
activity
A small portion of frozen ‘wet’ muscle was used
to determine PDC activity as previously described
Figure 1. Study protocol
Primed constant infusions of stable isotope-labelled AAs ([2H5]phenylalanine and [1,2-13C] leucine) were
administered for a total period of 240 min. Serum insulin was maintained at fasting concentrations (5 mU l−1)
for 120 min and endogenous insulin production was suppressed by infusion of octreotide, and post-absorptive
glucagon concentration was maintained by infusion of glucagon. After 120 min, serum insulin was raised
equivalent to a fed state (40 mU l−1). Quadriceps muscle biopsies were taken at baseline, 120 min and 240 min.
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(Constantin-Teodosiu et al. 1991). Briefly, the activity of
PDC in its dephosphorylated active form (PDCa) was
assayed in a buffer containing NaF and dichloroacetate,
and was expressed as a rate of acetyl-CoA formation
(mmol min−1 kg wet muscle−1) at 37°C.
Muscle mRNA expression
RNA was extracted from 30 mg snap-frozen muscle
as previously described (Mallinson et al. 2009). Taqman
low density arrays were performed in the ABI PRISM
7900HT sequence detection system and SDS 2.1 software
(Applied Biosystems, Foster City, CA, USA). Ninety-six
genes frompathways involved inCHOand fatmetabolism,
myogenesis, insulin signalling, proteolysis, autophagy,
apoptosis, inflammation and associated transcription
factors were determined. The candidate genes were chosen
from PubMed literature searches and data obtained from
our laboratory (Stephens et al. 2013). A complete list
of details for each gene is provided in Table 3. Data
were analysed using RQ Manager software (Applied
Biosystems) where the threshold level was normalised
across all plates before Ct values were calculated for each
gene and sample. Relative quantification of the genes
of interest was measured using the Ct method with
hydroxymethylbilane synthase (HMBS)as the endogenous
control. Ct values for HMBS were not different between
control and statin groups (data not shown). Differentially
expressed genes were identified by significance analysis of
microarrays (SAM) using false discovery rates (FDRs) of
5 and 1% and the maximum number of permutations
(24310) (MeV 4.5, TM4).
Figure 2. Body composition of control and statin user groups
Values are expressed as mean ± SEM. ∗P < 0.05 when comparing
arm fat mass, and †P < 0.05 when comparing trunk fat mass
between control and statin myalgic subjects.
Western blotting
Protein was extracted from 30 mg snap-frozen
tissue as previously described (Mallinson et al. 2012).
Total and phosphorylated 4EBP1 (Ser65) and p70S6k
(Thr389) (Cell Signaling, Danvers, MA, USA) and PDK4
(Millipore, UK) were analysed with anti-mouse IgG
(H+L) (DyLight 800 Conjugate, Cell Signaling) or
anti-rabbit IgG (H+L) (DyLight 680 Conjugate, Cell
Signaling) as the secondary antibodies. Blots were scanned
and bands identified using the Odyssey Infrared Imaging
System (LI-COR Biosciences, Lincoln, NE, USA). Dual
probing was used for total and phosphorylated proteins.
Density volumewas adjustedby subtracting the local back-
ground and then normalised with β-actin (Sigma Aldrich,
Dorset, UK).
Leucine incorporation into myofibrillar muscle protein
Myofibrillar leucine incorporation into muscle was deter-
mined using capillary gas chromatography–combustion
-–isotope-ratio mass spectrometry (GC-C-IRMS) using
our standard techniques (Kellis & Baltzopoulos, 1998).
Measurement of tissue free and plasma and AA
enrichment and concentration
Intracellular leucine enrichment was determined by
GC-MS as described previously (Burd et al. 2010).
To determine labelling (atom % excess) of plasma
leucine and phenylalanine, plasma proteins were pre-
cipitated with ice cold ethanol, and the supernatant,
containing free amino acids dried under N2, was
solubilised in 0.1 M HCl and the lipid fraction
extracted into ethyl acetate. The aqueous layer was
then dried under nitrogen and the tert-butyldimethylsilyl
(t-BDMS) derivative formed for analysis by GC-MS
(MD800; Fisons, Ipswich, UK) using electron impact
ionisation with selected ion monitoring. Blood leucine
and phenylalanine concentrations were determined using
GC-MS with reference to the appropriate standard
curves.
Calculations
Whole body glucose disposal. Whole body glucose
disposal (mg kg body mass−1 min−1) was calculated
during the fed state clamp once a steady state had been
reached (195–240 min) from the rate of glucose infusion
averaged over 5 min periods as described by DeFronzo
et al. (1979).
Leg glucose uptake. Leg glucose uptake (mg kg leg
lean mass−1 min−1) was calculated during the fed state
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Table 3. List genes used on low density RT-PCR array microfludic cards (Applied Biosystems Inc., Foster City, CA, USA)
Pathway Gene Protein ABI code
Carbohydrate metabolism CKM Creatine kinase Hs00176490 m1
LDHB Lactate dehydrogenase B Hs00929956 m1
NDUFS4 NADH dehydrogenase
(ubiquinone) Fe–S protein4
Hs00942568 m1
PDK4 Pyruvate dehydrogenase kinase,
isoenzyme 4
Hs00176875 m1
SLC2A4 GLUT4 Hs00268200 m1
Fat metabolism SLC22A5 Carnitine transporter OCTN2 Hs00161895 m1
CPT1B Carnitine palmitoyl transferase
1
Hs00993896 g1
FABP3 Fatty acid binding protein 3 Hs00269758 m1
FASN Fatty acid synthase Hs00188012 m1
HSPA5 Heat shock protein 70 kDa 5 Hs99999174 m1
NDUFA5 NADH dehydrogenase
[ubiquinone] 1 alpha
subcomplex subunit 5
Hs00606273 g1
PRKCA Protein kinase C alpha Hs00925195 m1
PRKCE Protein kinase C epsilon Hs00178455 m1
PRKCI Protein kinase C iota Hs00702254 s1
PRKCQ Protein kinase C theta Hs00989970 m1
SCD Stearoyl-coenzyme A
desaturase 1
Hs01682761 m1
FAT Fatty acid translocase/CD36 Hs00169627 m1
FDPS Farnesyl diphosphate synthase Hs00266635 m1
Insulin signalling Akt2 Protein kinase B/Akt, isoform 2 Hs01086102 m1
EIF2B2 Eukaryotic translation initiation
factor 2B, subunit 2 beta
Hs00204540 m1
MAP2K1 Mitogen-activated protein
kinase kinase 1
Hs00605615 mH
MAPK3 Mitogen-activated protein
kinase 3
Hs00385075 m1
PIK3R1 Phosphatidylinositol 3-kinase,
regulatory 1 (p85 alpha)
Hs00933163 m1
PRKAA1 A-Kinase, cAMP-dependent
protein kinase,
Hs01562308 m1
RASA1 p21 Ras Hs00243115 m1
RHOQ Ras homologue gene family,
member Q
Hs00817629 g1
RRAGA Ras-related GTP binding A Hs00538975 s1
Oxidative phosphorylation/ETC COX7A1 Cytochrome c oxidase subunit
VIIa polypeptide 2
Hs00156989 m1
CYCS Cytochrome c Hs01588974 g1
MT-CO1 COX-I, Cytochrome c oxidase I Hs02596864 g1
MT-CO2 COXII, Cytochrome c oxidase 2 Hs00153133 m1
UQCRQ Coenzyme Q-cytochrome c
reductase, complex III
Hs00416927 g1
SDHA Complex II, succinate
dehydrogenase
Hs00188166 m1
CoQ10B Ubiquinone/CoQ10 Hs00257861 m1
Transcription factor FOXO1A Forkhead transcription factor
1A
Hs00231106 m1
FOXO3 Forkhead transcription factor 3 Hs00818121 m1
MEF2C Myocyte specific enhancer
factor 2
Hs00231149 m1
MYOD1 Myogenic factor 3 Hs00159528 m1
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Table 3. continued
Pathway Gene Protein ABI code
MYOG Myogenin Hs00231167 m1
PPARA Peroxisome
proliferator-activated
receptor alpha
Hs00231882 m1
PPARD Peroxisome
proliferator-activated
receptor beta
Hs00602622 m1
PPARG Peroxisome
proliferator-activated
receptor gamma
Hs01115513 m1
PPARGC1A Peroxisome
proliferator-activated
receptor-gamma coactivator
1 alpha
Hs01016724 m1
RELA NF-kappaB3 Hs00153294 m1
SREBF2 Sterol regulatory element
binding protein 2
Hs01081778 m1
SREBP1c Sterol regulatory element
binding protein 1c
Hs01088691 m1
ATF3 Activating transcription factor 3 Hs00231069 m1
Transcription factor NFKB1 Nuclear factor of kappa light
polypeptide gene enhancer in
B-cells 1
Hs00765730 m1
NFKB2 Nuclear factor of kappa light
polypeptide gene enhancer in
B-cells 2
Hs01028894 m1
IKKbeta Inhibitor of kappa light
polypeptide gene enhancer in
B-cells, kinase beta
Hs00233287 m1
AP1 jun proto-oncogene Hs00277190 s1
Myogenesis ROCK1 ROCK Hs00178463 m1
RHOA Ras homolog gene family,
member A
Hs00236938 m1
RHOB Ras homolog gene family,
member B
Hs00269660 s1
MYF5 Myogenic factor 5 Hs00271574 m1
HRAS Transforming protein p21 Hs00610483 m1
MET Met proto-oncogene Hs01565584 m1
CDH15 m-cadherin 15 Hs00170504 m1
RHEB Ras homolog enriched in brain Hs00950800 m1
CD34 CD34 Hs00990732 m1
Autophagy GABARAP GABA(A) receptor-associated
protein
Hs00925899 g1
TFAM Transcription factor A,
mitochondrial
Hs01082775 m1
BNIP3 BCL2/adenovirus E1B 19 kDa
interacting protein 3
Hs00969291 m1
DRP1 Dynamin 1-like Hs00247147 m1
Proteolysis CAST Calpastatin Hs00156280 m1
UBB Ubiquitin-B Hs00430290 m1
UBC Ubiquitin-C Hs00824723 m1
MAFbx F-box protein 32 Hs01041408 m1
TRIM63 MuRF1 Hs00261590 m1
PSMA beta 1 Proteasome subunit beta type 1 Hs00427357 m1
PSMA beta 2 Proteasome subunit beta type 2 Hs01002946 m1
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Table 3. continued
Pathway Gene Protein ABI code
PSMA beta 5 Proteasome subunit beta type 5 Hs00605652 m1
USP19 Ubiquitin specific peptidase 19 Hs00324123 m1
CAPN1 Calpain 1 Hs00559804 m1
CAPN2 Calpain 2 Hs00965092 m1
CAPN3 Calpain 3 Hs00544975 m1
MSTN Myostatin Hs00976237 m1
CTSL1 Cathepsin L Hs00377632 m1
MMP2 Matrix metallopeptidase 2 Hs01548727 m1
Apoptosis CASP9 Caspase-9 Hs00154261 m1
CASP8 Caspase-8 Hs01018151 m1
Smac/Diablo Diablo IAP-binding
mitochondrial protein
Hs00219876 m1
APAF-1 Apoptotic peptidase activating
factor 1
Hs00559441 m1
BCL2 B-cell CLL Hs00608023 m1
Inflammation TNF Tumour necrosis factor α Hs99999043 m1
Il-6 Interleukin-6 Hs00985639 m1
MT1A Metallothionein 1A Hs00831826 s1
Calcium release RYR1 Ryanodine receptor 1 Hs00166991 m1
RYR3 Ryanodine receptor 3 Hs00168821 m1
Organic anion transporter SLCO1B1 Solute carrier organic anion
transporter family, member
1B1
Hs00272374 m1
Housekeeping gene ACTA1 Actin, alpha Hs00559403 m1
HMBS Hydroxymethylbilane synthase Hs00609297 m1
B2M Beta2-microglobulin Hs00187842 m1
POLR2A RNA polymerase 2a Hs01108291 m1
clamp once a steady state had been reached using the
equation (AV glucose concentration – venous glucose
concentration) × leg blood flow/leg lean mass.
Muscle protein synthesis (MPS) or fractional synthetic
rate. The rate ofMPS between the biopsies was calculated
using the standard equation of fractional protein synthesis
(% h−1), Em/Ep (1/t) × 100, where Em is the
change in labelling of muscle protein leucine between
two biopsy samples, Ep is the mean enrichment over
time of the precursor for protein synthesis (taken
as intraceullar leucine) and t is the time between
biopsies.
Leg protein breakdown (LPB). LPB was calculated from
the AV dilution of [2H5]phenylalanine tracer AA using the
following equation: [(Ea/Ev) – 1]× 2Cv ×BF,whereEa and
Ev are the values of phenylalanine labelling at steady state
in AV and femoral venous blood, respectively, Cv is the
concentration of phenylalanine in femoral venous blood,
and BF is the blood flow in ml per leg. Leg lean mass (kg)
was calculated from thedual-energyX-ray absorptiometry
scans.
Statistics
All data are expressed as mean ± SEM. An independent
samples Student’s t-test was used to compare differences
between groups. For repeated measures, a repeated
measures general linear model (GLM) was used and a
least significance difference post hoc test was performed
to locate significant differences. Score data were analysed
with a Mann Whitney U test and a Pearson’s correlation
coefficientwasused todetermine any relationshipbetween
fat mass and glucose disposal rate. A significance level of
P < 0.05 was used. All calculations were performed using
IBM SPSS 19.0.
Results
Physical characteristics, clinical chemistry and body
composition
Clinical chemistry showed no significant differences in
plasma CK, lactate dehydrogenase (LDH), interleukin 6
(IL6) or tumour necrosis factor α (TNFα) levels between
groups (Table 1), although the magnitude of perceived
muscle soreness was 4-fold greater in the statin myalgic
subjects (P < 0.001). Muscle total creatine and ATP
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content was also similar between control and statin
myalgic subjects (Table 1).
There was no difference in regional (arm, trunk, leg)
lean tissue mass (Fig. 2) when comparing control and
statin myalgic subjects. However, arm and trunk fat mass
was significantly greater in statin myalgic subjects (Fig. 2,
P < 0.05).
Muscle functional measurements
Isometric strength of the knee extensors was not different
between control and statin myalgic subjects (Fig. 3A).
Similarly, peak power output during 30 maximal knee
extensor contractions was not different between groups
(Fig. 3B). However, whilst the control group achieved
peak power at the third contraction, the statin user group
achieved peak power output at the twelfth contraction,
producing significantly less work output per contraction
at the onset of exercise (Fig. 3C, P < 0.05).
Serum insulin concentration, whole body and leg
glucose disposal, and muscle pyruvate
dehydrogenase complex regulation
When serum insulin was clamped at a fasting
concentration for 2 h (insulin infusion rate of
0.6 mU m2 min−1), no difference in steady-state serum
insulin concentration was seen when comparing control
and statin user groups (data not shown). Similarly, when
the insulin infusion ratewas increased to 40mUm2min−1,
along with AA infusion at 10 g h−1 to create a fed state
condition, no difference in steady-state serum insulin
concentrationwasobserved, although therewas a trend for
the area under the steady-state insulin curve to be greater
in the statin user group (Fig. 4A, P = 0.07), probably
reflecting blunted insulin clearance in statin myalgic
subjects, given that endogenous insulin production was
suppressed by octreotide infusion (seeMethods). The rate
of whole body glucose disposal during the fed state insulin
clamp was 30% lower in the statin user group compared
to control (Fig. 4B, P = 0.05) and was accompanied by
leg glucose uptake being 45% lower in the statin group
(Fig. 4C, P < 0.01). A negative correlation was seen
between whole body glucose disposal and trunk fat mass
(Fig. 4D, r = –0.70, P < 0.01). The fed state insulin
clamp tended to increase muscle PDC activity, but this
was not significantly different from baseline or between
groups (Table 4). Muscle PDK4 protein expression was
not different between control and statin myalgic subjects
at baseline or after both fasted and fed state insulin clamps
(Table 4).
Figure 3. Muscle functional measurements in control and statin user groups
A, isometric strength (kg kg leg lean mass−1); B, peak power output (W kg leg lean mass−1); C, peak isokinetic
work per contraction (Nm) during 30 maximal isokinetic contractions. Values are expressed as mean ± SEM.
∗P < 0.05 compared to control.
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Table 4. Muscle PDC activity and PDK4 protein expression in control and statin user groups at baseline, after a 2 h fasted state insulin
clamp and a 2 h fed state insulin clamp
Control (n = 9) Statin (n = 9)
PDC activity (mmol min−1 kg−1)
Baseline 0.55 ± 0.08 0.41 ± 0.09
Fasted clamp 0.49 ± 0.09 0.41 ± 0.07
Fed clamp 0.67 ± 0.12 0.57 ± 0.13
PDK4 protein expression (mean intensity)
Baseline 0.61 ± 0.17 0.37 ± 0.05
Fasted clamp 0.45 ± 0.09 0.44 ± 0.05
Fed clamp 0.59 ± 0.24 0.51 ± 0.07
All values expressed as mean ± SEM. Within- and between-group effects are all non-significant.
MPS and LPB
The rate of MPS was similar between control and
statin myalgic subjects during the fasting insulin clamp
(Fig. 5A). As expected, the fed state clamp nearly doubled
MPS (P < 0.001 for both groups), but the magnitude
of the increase was not different between groups
(Fig. 5A). LPB was not different between the control and
statin myalgic subjects during the fasting insulin clamp
(Fig. 5B). Furthermore, no statistical difference was seen
when comparing treatment groups during the fed state
insulin clamp, although the average reduction in LPB by
insulin was greater in the statin myalgic subjects (Fig. 5B),
probably reflecting the trend for steady-state serum insulin
concentration to be greater in this group (Fig. 4A).
Figure 4. Serum insulin concentration and blood glucose disposal rate in control and statin user groups
A, serum insulin area under the curve (AUC) (μIU ml−1 min−1) during the period of steady-state glucose disposal
of the fed state clamp (40 mU m−2 min−1 insulin and 10 g h−1 mixed amino acids); B, rate of steady-state whole
body glucose disposal (mg kg−1 min−1) during the fed state clamp; C, rate of steady-state leg glucose uptake
during the fed state clamp (mg kg−1 leg lean mass min−1); D, relationship between whole body glucose disposal
(mg kg−1 min−1) and trunk fat mass (kg). Closed circles = control, open circles = statin myalgic subjects. All values
are expressed as mean ± SEM. ∗∗P < 0.01 compared to control.
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Muscle anabolic signalling
Therewas no change in the ratio ofmuscle phosphorylated
to total p70S6k protein expression from basal during the
fasted state insulin clamp when comparing control and
statin myalgic subjects. The fed state clamp tended to
increase p70S6k protein phosphorylation in statinmyalgic
subjects above control (P= 0.08, Fig. 6A). Similarly, there
was no change from basal in the ratio of phosphorylated
to total 4EBP1 protein expression during the fasted state
insulin clamp in both experimental groups. However,
4EBP1 phosphorylation was significantly greater in the
statin myalgic subjects at the end of the fed state clamp
relative to the control group (P<0.05, Fig. 6B).Thegreater
phosphorylation status of p70S6k and 4EBP1 at the end of
the fed state clamp in the statinmyalgic subjects relative to
control probably reflects the trend for steady-state serum
insulin concentration to be greater in the statin group
(Fig. 4A).
Figure 5. Muscle protein synthesis and leg protein breakdown
in control and statin user groups
A, rate of muscle protein synthesis (fractional synthetic rate, FSR)
during a 2 h fasted state insulin clamp (0.6 mU m−2 min−1 insulin)
and a 2 h fed state insulin clamp (40 mU m−2 min−1 insulin and
10 g h−1 mixed AAs); B, rate of leg protein breakdown during a 2 h
fasted state and a 2 h fed state insulin clamp. Values are expressed
as mean ± SEM. ∗∗∗P < 0.001 when fasted vs. fed clamp.
Taqman low density array analysis
Following SAM analysis, mRNA expression of 33 genes
was significantly (P < 0.05) up-regulated in the muscle
of the statin myalgic subjects compared to control when
employing a 5% FDR, and no genes were found to
be down-regulated. The major pathways up-regulated
were proteolysis and apoptosis (Fig. 7A), CHO and fat
metabolism (Fig. 7B), cell migration and proliferation
(Fig. 7C), transcription factors (Fig. 7D) and insulin
signalling (Fig. 7E). The magnitude of the fold increase
was generallymodest (ranging from1.1- to1.8-fold greater
than control), but six genes were found to be up-regulated
using a 1% FDR. These genes were MMP2, RhoB, BCL2,
SREBF2, myostatin (MSTN) and CK. In the case of CK,
Figure 6. Expression levels of proteins involved in translation
initiation of muscle protein synthesis in skeletal muscle in
control and statin user groups
A, ratio of muscle phosphorylated to total p70S6k protein
expression; and B, ratio of muscle phosphorylated to total 4EBP1
protein expression. ∗P < 0.05 compared to control within the fed
state clamp. Values are expressed as mean intensity (normalised to
β-actin) ± SEM.
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a profound mean increase in mRNA expression (89-fold)
was evident compared to control, with all statin myalgic
subjects displaying a striking increase inmuscleCKmRNA
expression relative to control, which ranged from55- to
130-fold (Fig. 7F).
Discussion
To our knowledge, this is the first study to measure
muscle protein turnover rates and insulin sensitivity in
statin myalgic subjects using gold standard methods. We
provide novel and important insight by demonstrating
that statin myalgia in older people is not associated
with deficits in muscle strength and lean mass or
the dysregulation of muscle protein turnover when
compared to age-matched, non-statin user controls.
Furthermore, there were no between-group differences
in systemic or muscle inflammatory markers. However,
statin myalgia was associated with a delay in time to
peak power output during repeated maximal contra-
ctions, increased central adiposity and whole body and
leg insulin resistance, and increased expression of muscle
mRNAs (which was profound in the case of muscle CK
mRNA).
Muscle function in individuals presenting with statin
myopathy and myalgia has been examined previously,
although the data are equivocal, in that statin myalgic
subjects showed either limited changes inmuscle function
compared to non-statin users (Parker et al. 2012), or
exhibited signs of reduced muscle strength leading to
an increased risk of falls (Scott et al. 2009). The pre-
sent study revealed no difference in quadriceps isometric
strength between control and statin myalgic subjects
(Fig. 3A), and accordingly no between-group difference in
leg leanmass (Fig. 2). Similarly, peak power output during
30 maximal knee extensor contractions was not different
betweengroups (Fig. 3B).However, the time taken to reach
peak power was greater in statin myalgic than in control
volunteers (twelfth contraction vs. third contraction,
respectively, Fig. 3B), such that the statin myalgic subjects
generated significantly less work output per contraction
at the onset of exercise (Fig. 3C, P < 0.05). This response
confirms the presence of exercise intolerance in statin
myalgia, most probably due to joint- and muscle-related
discomfort at the initiation of exercise. This interpretation
is supported by our observation that the magnitude of
perceived muscle soreness at rest was 4-fold greater in the
statin user group compared to control (Table 1,P< 0.001).
Statin use has been linked to an increased incidence
of type 2 diabetes (Preiss et al. 2011), and simvastatin in
particular has been shown to decrease insulin sensitivity
in hypercholesterolaemic patients (Koh et al. 2008),
as determined by the Quantitative Insulin Sensitivity
Check Index (QUICKI), and to impair glucose tolerance
during an oral glucose challenge (Larsen et al. 2013).
The present study is the first to utilise a gold standard
assessment of insulin sensitivity (DeFronzo et al. 1979)
to determine whether statin myalgic subjects present
with reduced glucose disposal compared to healthy
age-matched control volunteers.We show that steady-state
wholebodyglucosedisposal under ‘fed state’ insulin clamp
conditions was 30% lower in statin myalgic subjects even
in the face of greater circulating insulin concentrations
(Fig. 4A and B). Furthermore, leg glucose uptake was
45% lower in the statin myalgic subjects (Fig. 4C).
This lower insulin-stimulated glucose disposal was not
paralleled by increased muscle PDK4 protein expression
(Table 4) or blunted activation of muscle PDC (Table 4),
clearly suggesting the insulin resistance observed does
not reside at the level of PDC activation as has pre-
viouslybeenproposed inhigh fat feeding-mediated insulin
resistance (Mayhew et al. 1995). Nevertheless, we did
observe increased expression of insulin signalling mRNAs
in the statin user group, namely MAPK3, MAP2K1
(Fig. 7E) andFOXO3(Fig. 7D), suggesting a compensatory
adaptation to the heightened insulin resistance observed
in these statin myalgic subjects. There is increasing
evidence that abdominal adiposity is more closely linked
to the development of insulin resistance (Kohrt et al.
1993), possibly as a result of increased hepatic fatty
acid flux stimulating gluconeogenesis and inhibiting
hepatic insulin clearance. Indeed, trunk fat mass was
inversely related to whole body glucose disposal rates
across all volunteers during the ‘fed state’ insulin
clamp in the present study (Fig. 4D). Furthermore,
steady-state serum insulin concentration tended to be
greater in the statin myalgic subjects, who also presented
with greater abdominal adiposity compared to controls
(Fig. 2). These observations cannot, however, explain the
lower leg glucose uptake in the statin myalgic group,
particularly given leg lean and fat masses were the same.
Reduced physical activity impacts heavily on quality
of life, increasing morbidity and overall mortality (Wen
et al. 2011). There is also increasing evidence that physical
inactivity is causative in the development of insulin
resistance and type 2 diabetes (Bergouignan et al. 2011)
and that this can be mediated by a relatively rapid
direct effect of inactivity per se (Johnson et al. 1976),
along with a more chronic inactivity-induced increase in
adiposity. The experimental design of the current study
does not allow insight into whether the statin myalgic
group was more insulin resistant upon entry into the
study, whether statin use per se was responsible for the
insulin resistance observed, or whether a statin-mediated
reduction in physical activity levels because ofmuscle pain
and discomfort was a contributing factor. However, given
the increasing incidence of type 2 diabetes with statin use,
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further research is warranted to determine the relative
contribution of each to the aetiology of statin-associated
insulin resistance, particularly given increased physical
activity levels are thought to exacerbate statin-related
muscle pain and discomfort (Parker et al. 2012). Indeed,
emerging evidence from large cohort cross-sectional and
longitudinal studies (Lee et al. 2014) does support the
view that statin myalgia in older people is associated with
lower habitual physical activity, even after accounting
for medical history and other potentially confounding
factors. Furthermore, there is clear evidence that patients
with musculoskeletal dysfunction associated with chronic
non-communicable disease (e.g. chronic obstructive
pulmonary disease, osteoarthritis and fibromyalgia) have
Figure 7. Muscle mRNA expression normalised to HMBS in the statin user group relative to control at
baseline (fold change)
A–E, SAM analysis, using an FDR of 5%, revealed these genes to be significantly up-regulated in statin myalgic
subjects. Values are expressed as mean ± SEM. Control values are set at 1 and are represented as a dotted
line. F, muscle creatine kinase mRNA expression normalised to HMBS (fold change relative to control). Values are
expressed as mean ± SEM (black horizontal bar) and individual fold difference in statin myalgic subjects (black
spots). ∗∗∗P < 0.001 when compared to control.
C© 2014 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 593.5 Statin myalgia, muscle function and metabolism 1253
lower habitual physical activity levels compared to healthy
controls (Tudor-Locke et al. 2009). In line with this
evidence, the statinmyalgic volunteers in the present study
presented with increased muscle soreness (Table 1) and
a delay in time to peak power output during repeated
maximal, voluntary contractions (Fig. 3C). Furthermore,
themuscle pain questionnaire used at screening (based on
the McGill pain questionnaire; Melzack, 1975) revealed
six of the nine statin myalgic volunteers reported walking
or lifting as activities that exacerbate their muscular
symptoms, and that the alleviation of symptoms occurred
with rest and pain medication (Table 2). Collectively, it
is not therefore unreasonable to assume that habitual
physical activity levels would have been lower than that
of the control volunteers in the present study. However,
if adiposity and reduced physical activity were indeed
principal drivers of the muscle insulin resistance in the
statin myalgic group of the present study, one would have
expected this cohort to show a blunting of the muscle
protein synthetic response to increased nutrient delivery
(Breen et al. 2013), which was clearly not evident in the
present study (Fig. 5A).
Limited studies have examined global gene expression
in skeletal muscle of individuals on statin therapy
(Urso et al. 2005; Laaksonen et al. 2006), and none
in individuals presenting with overt statin myopathy
or myalgia. In the present study, a micro-fluidic card
approach was used to quantify mRNA abundance of
genes covering a number of signalling and metabolic
pathways in skeletal muscle to shed light on the molecular
basis of statin myalgia. Of the 96 mRNAs quantified,
33 were in greater abundance in the statin user group
compared to control (Fig. 7; 5% FDR), albeit moderately
(1.07- to 1.43-fold increase). None was found to be
in less abundance. Twenty-seven per cent of these 33
differentially expressed genes were found to be involved in
proteolysis/apoptosis pathways. This observation concurs
with the report of Laaksonen et al. (2006) in which high
dose simvastatin administration (80mg day−1) resulted in
differential expression of 111 genes from predominantly
pro-apoptotic pathways compared to placebo and low
dose atorvastatin (40 mg day−1) administration, but sub-
jects reported no statin-related side effects, i.e. muscle
pain or serum CK elevation. In the present study, several
transcription factors (Fig. 7D) and mRNAs concerned
with CHO/fat metabolism (Fig. 7B), myogensis (Fig. 7C)
and insulin signalling (Fig. 7E) were also found to be in
greater abundance in the statin myalgia group.
Plasma CK and lactate dehydrogenase protein are
routinely used as markers of muscle disruption, but the
concentration of both was within the normal range in
the present study and no difference was observed between
experimental groups (Table 1). This was contrasted by the
striking between-group difference in muscle CK mRNA
expression, which was between55- and 130-fold greater
in the statin user group (Fig. 7F). Increased muscle CK
expression is commonly related to mitochondrial myo-
pathies (Stadhouders et al. 1994), and in the context of the
present study statin administration has been associated
with muscle mitochondrial disruption in animal and cell
culture experiments (Bouitbir et al. 2011), and impaired
mitochondrial respiration in human volunteer studies
(Larsen et al. 2013). Of further note, four of the six genes
found to be up-regulated at the 1% FDR in the present
study, RhoB, BCL2, MMP2 and myostatin, have been
linked to mitochondrial apoptotic signalling (Bigland
& Lippold, 1954). Indeed, it has been suggested that
simvastatin (Zo¨rgiebel et al. 2007) andmyostatin (Bigland
& Lippold, 1954) trigger the mitochondrial pathway of
apoptosis via translocation of Bax from the cytosol to
the mitochondrial membrane, and simvastatin-mediated
up-regulation of RhoB mRNA and protein levels is
paralleled by caspase 2 activation (Zo¨rgiebel et al. 2007).
In keeping with this, mysotatin knockout mice have
abnormal mitochondrial function (Ploquin et al. 2012). It
may be speculated therefore that the marked upregulation
of CK mRNA in the statin myalgic subjects in the present
studymay have occurred as a protective adaptation against
apoptosis, i.e. a compensatorymeasure tomaintain proper
cell function (Schlattner et al. 2006).
To our knowledge, this is the first study to measure
muscle protein turnover rates and associated molecular
pathways in statin myalgia. The molecular mechanisms
responsible for statin myopathy are poorly defined,
particularly in vivo. We have previously demonstrated
that simvastatin administration inhibits muscle PI3k/Akt
signalling, concomitantly with the dephosphorylation
(activation) of muscle FOXO transcription factors and
increased mRNA abundance of muscle genes thought to
regulate proteasomal and lysosomally mediated protein
degradation and the suppression of CHO oxidation in a
rodent model of statin myopathy (Mallinson et al. 2009,
2012). In keeping with this, statin myalgia in the pre-
sent study was associated with increased expression of
genes involved in muscle proteolysis (MuRF1, MMP2),
apoptosis (Caspase 8/9, BCL2, RhoB, MMP2, myostatin)
and autophagy (TFAM, BNIP3) (Fig. 7). However, these
differences in mRNA abundance were modest and did
not translate into increased leg protein breakdown, even
under post-absorptive state conditions where the rate of
leg protein breakdown would predominate over synthesis
(Fig. 5B), or reduced leg lean mass (Fig. 2). It is therefore
plausible that the catabolic gene mRNA abundance
changes linked to proteolysis, autophagy and apoptosis
reflect preliminary stages in the progression from statin
myalgia to myopathy (particularly in the case of the latter
where four of the six genes up-regulated at a 1% FDR
have been previously linked to mitochondrial apoptotic
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signalling). Clearly, longitudinal studies are warranted to
interrogate this suggestion in greater detail.
In keeping with the post-absorptive leg protein break-
down responses and lack of difference in muscle mass
between statin myalgia and control volunteers, the
post-prandial increase in muscle protein synthesis was
not blunted in statin myalgia, and contrasts what might
have been expected based on the disruption of PI3k/Akt
signalling in rodent statinmyopathy (Mallinson et al. 2009,
2012). Indeed, statin myalgic subjects in the present study
showed no inactivation of the anabolic signalling proteins,
p70S6k (Fig. 6A) and 4EBP1 (Fig. 6B), but paradoxically
showed increased phosphorylation of 4EBP1 and p70S6k
in response to feeding. The greater phosphorylation
status of p70S6k and 4EBP1 at the end of the fed
state clamp in the statin user group relative to control
probably reflects the trend for steady-state serum insulin
concentration to be greater in the statin group (Fig. 4A).
Wehave previously demonstrated this associationbetween
the phosphorylation status of p70S6k and 4EBP1 and
steady-state serum insulin concentration, which can be
dissociated from themuscle protein synthetic response to a
fed state condition (Greenhaff et al. 2008). The expression
levels of muscle myogenic mRNAs were upregulated
in statin myalgic subjects, for example RhoB, HRAS,
CDH15 (Fig. 7C) and myogenin (Fig. 7D). However,
again the magnitude of the increase, although significant,
was small and was not associated with between-group
differences in muscle mass or protein synthetic responses.
Of note, however, after CK, myostatin was the most
abundantly expressed gene in the statin myalgic sub-
jects, and remained significantly upregulated when using
a 1% FDR. Myostatin functions as a negative regulator
of satellite cell proliferation and differentiation, and
muscle growth and development (Lee & McPherron,
2001). Moreover, increased myostatin mRNA expression
appears to be a common feature of human muscle
wasting in critical illness (Constantin et al. 2011) and
chronic muscle disuse (Reardon et al. 2001). Whilst this
is the first study to demonstrate increased myostatin
mRNA expression in statin myalgia, the statin myalgia
group showed no evidence of elevated muscle protein
breakdown or lower lean body mass. However, myo-
statin has also been associated with the regulation of
muscle insulin sensitivity, with myostatin-deficient mice
exhibiting increased insulin sensitivity (through activating
the AMP-activated protein kinase signalling) (Zhang et al.
2011), which is in agreement with insulin resistance
being greater in the statin myalgic group of the present
study. Indeed, it has recently been demonstrated that
increasing myostatin potently induces hepatic and muscle
insulin resistance in rodents by degrading IRS1 protein
(Bonala et al. 2014) and reducing signalling through the
Akt/p70S6k pathway in myotubes (Trendelenburg et al.
2009).
Finally, it has recently been suggested that glycine
amidinotransferase (GATM), a gene that encodes the
rate-limiting enzyme in creatine synthesis, may be the
functional link between statin-mediated lowering of
cholesterol and susceptibility to statin-induced myopathy
(Mangravite et al. 2013). The authors found GATM to
be associated with the incidence of statin-induced myo-
toxicity in two separate populations. Moreover, GATM
knockdown in hepatocyte-derived cell lines attenuated the
transcriptional response to sterol depletion. This suggests
a potential association between creatine synthesis and
statin myopathy. However, we found no difference in
muscle total creatine or muscle ATP content between
control and statinmyalgic subjects (Table 1). Furthermore,
given creatine synthesis is localised to the liver, it is
difficult to rationalise the association between GATM and
statin-related muscle problems, particularly when muscle
total creatine stores appear to be normal in statin myalgia
(Table 1).
In summary, we have shown the presence of a
delay in the time to reach peak power output in
older, male chronic statin myalgic subjects compared
to age-matched volunteers, but there was no evidence
that this phenomenon was linked to the presence of
systemic or muscle inflammation or the disruption of
muscle protein turnover and the loss of muscle mass and
strength.However, statinusewas associatedwith increased
abdominal adiposity, insulin resistance and evidence
supporting the advent of mitochondrial dysfunction
and apoptosis, which warrants further investigation
particularly in relation to statin myalgia potentially
reducing habitual physical activity levels and therefore
increasing cardiovascular risk.
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